The Effect of Whole Blood Viscosity on Contrast-Induced Nephropathy Development in Patients Undergoing Percutaneous Coronary Intervention

Percutaneous Coronary Intervention Patients Clinical Trial

Official title:

The Effect of Whole Blood Viscosity on Contrast-Induced Nephropathy Development in Patients Undergoing Elective Percutaneous Coronary Intervention

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04703049
• Other study ID #: YIEAH
• Status: Completed
• Start date: July 10, 2017
• Est. completion date: November 30, 2017

Study information

• Verified date: August 2021
• Source: Bursa Postgraduate Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In our study, we aimed to investigate how whole blood viscosity (WBV) affects the development of contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary intervention (PCI).

Description:

In our study, 500 patients who applied to the cardiology clinic and underwent PCI for elective procedure, ST segment elevation myocardial infarction (STEMI), and non-STEMI were prospectively included. Before the procedure, we calculated WBV using the formula [(0.12 × hematocrit) + (0.17 × (total protein - 2.07)]. We defined CIN as the absolute (≥0.5 mg/dl) or relative increase (≥25%) in serum creatinine 48-72 h after exposure to a contrast agent compared with baseline serum creatinine values.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 500
• Est. completion date: November 30, 2017
• Est. primary completion date: October 31, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• patients between ages 18 and 90

• underwent PCI in our hospital between

Exclusion Criteria:

• Patients with chronic kidney disease (CKD) who underwent hemodialysis or peritoneal dialysis

• Patients who underwent to coronary bypass surgery within 48 h were excluded from the study.

Related Conditions & MeSH terms

• Kidney Diseases
• Percutaneous Coronary Intervention Patients

Intervention

Other:
• Blood Viscosity Testing
we calculated WBV using the formula [(0.12 × hematocrit) + (0.17 × (total protein - 2.07)]. We defined CIN as the absolute (=0.5 mg/dl) or relative increase (=25%) in serum creatinine 48-72 h after exposure to a contrast agent compared with baseline serum creatinine values.

Locations

Country	Name	City	State
Turkey	Bursa Yüksek Ihtisas Hastanesi	Bursa	None Selected

Sponsors (1)

Lead Sponsor	Collaborator
Bursa Postgraduate Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Contrast Induced Nephropathy	CIN was defined as an increase in serum creatinine levels greater than 0.5 mg/dl or 25% or more increase compared to basal serum creatinine levels 48 to 72 h after exposure.	48 to 72 hours